Navigation Links
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
Date:6/14/2008

Soliris therapy, all patients and their prescribing physicians are enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at http://www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris, for all patients with PNH, and Alexion began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the EC granted marketing approval for Soliris in the European Union for all patients with PNH. Alexion is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliri
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
4. Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
5. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
6. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
7. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
8. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
9. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
Breaking Medicine Technology:Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... /PRNewswire/ -- A new study suggests,strong variation in ... U.S. Anaphylaxis is a severe allergic,reaction that can ... differences in EpiPen prescribing, a marker of,anaphylaxis risk, ... low levels of vitamin D,from lack of sunshine, ...
... ,Celiac disease (CD) is an autoimmune inflammatory disease ... genetically susceptible persons by the ingestion of the ... The condition is thought to result from the ... response, leading to mucosal inflammation, villous atrophy, and ...
Cached Medicine Technology:Large Geographic Differences in EpiPen Prescriptions in the U.S.,From the Journal of Allergy and Clinical Immunology 2Non-Invasive Diagnostic Tests for Celiac Disease 2Non-Invasive Diagnostic Tests for Celiac Disease 3
(Date:7/14/2014)... New York, NY (PRWEB) July 14, 2014 ... authority Danny Seo and Harris Publications, debuts with a ... The lifestyle magazine looks at living the healthy, ... authoritative voice that covers everything from food, beauty, travel, ... America’s leading guru of green living. , “Instead of ...
(Date:7/14/2014)... According to the Blood Pressure Solution book ... that features a series of new information on high ... this book can help readers understand more about blood pressure. ... and effective methods to control hypertension naturally. ... Vkool, was penned by Ken Burge, a medical researcher and ...
(Date:7/14/2014)... July 14, 2014 Vaginal Mesh ... against seven different pelvic mesh manufacturers in the U.S. ... & Schulte LLC. The federal complaints are pending against ... 2327), American Medical Systems (MDL No. 2325), and C.R. ... there are 58,262 Vaginal Mesh lawsuit claims pending, according ...
(Date:7/14/2014)... TherapySites, the leading ... professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue ... members, adding exclusive benefits and promotional offers. , ... dedicated to providing online marketing solutions specifically for ...
(Date:7/14/2014)... July 14, 2014 Townsend Security, ... announced its new IBM i (AS/400, iSeries) Two ... (ISVs). As security threats evolve and make passwords ... struggle to modernize their applications and implement two ... makes it easy for ISVs on the IBM ...
Breaking Medicine News(10 mins):Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 3
... another bout of West Nile, a potentially fatal, mosquito-spread infection. ... Control of the Harris county has said that the situation ... is still a large percentage of people in Houston who ... repellants or going out at night in short-sleeve shirts can ...
... out with the report that with UK leading the group, cancer ... use of new drugs. ,The study termed uptake of ... as well as in New Zealand, Poland, Czech Republic and South ... US were leaders in using new cancer drugs. ,The ...
... forty per cent (37 per cent) of British women and a ... unattractive on holiday as a result of excessive exposure to the ... has been conducted to highlight Sun Awareness Week, which kicks off ... over unsightly sunburn has meant that one in three Brits could ...
... eyes, say experts, who advise frequent short breaks every half ... ,Studies have shown that eyestrain and other vision problems ... people using video display terminals at work, said Kerry Beebe, ... ,The most common symptoms are eyestrain, blurred vision, ...
... the brakes on a racing heartbeat. ... the May 11 issue of Circulation Research how an enzyme ... of the heart's "fight-or-flight" reaction to adrenaline. ,A ... setting the pace of the beating heart, triggering its neighbor ...
... who is on a visit to the US, has ... in Hyderabad, promising to provide all necessary infrastructure. ... the signing of an MoU between Stanford University, the ... Research Institute) in California Thursday. ,Under the ...
Cached Medicine News:Health News:Health Authorities Fear West Nile Season Again in US 2Health News:Britains Complacent Attitude To Uptake Of New Cancer Drugs Revealed 2Health News:Burnt Brits Don't Feel Hot 2Health News:Many Hours on Computer may Harm Eyes 2Health News:Slowing the Racing Heart 2Health News:Reddy Asks Stanford University to Open Hyderabad Campus 2
... TFC Unite Device is the anterior alternative to ... Unite device features the same 70% fenestrations as ... fenestrations is paramount in the formation of new ... Unite system promotes load sharing between the device ...
Steinmann Pins are available in six point styles ranging from 5/64 to 3/16 in. diameters, in standard 9 in. (230 mm) lengths with threaded and smooth tips. Material: DePuy certified stainless steel. ...
... implant is the only approved radiolucent stand-alone ... assessment with the proven reliability of the ... Vista System is constructed of radiolucent, carbon-fiber ... unobstructed radiologic visualization, providing a new level ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Medicine Products: